Conversely, patients with SLE and LN demonstrated higher utilization rates of glucocorticoids, mycophenolate mofetil, calcineurin inhibitors, and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers. This evidence concerns the gene ACE and systemic lupus erythematosus.